Business
NetworkNewsWire Announces Publication that Highlights the Limitless Potential of Innovative Drug Development
New York, New York--(Newsfile Corp. - October 3, 2017) - NetworkNewsWire ("NNW"), a multif...
About this update from Infield Minerals Corp
[{"type":"text","content":"NetworkNewsWire Announces Publication that Highlights the Limitless Potential of Innovative Drug DevelopmentNew York, New York--(Newsfile Corp. - October 3, 2017) - NetworkNewsWire (\"NNW\"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.The publication, titled, \"Cannabinoid Biosynthesis Poised as Potential Game-Changer in Drug Development,\" discusses companies developing medicines through the new access to every cannabinoid compound. To view the full publication, visit: https://www.networknewswire.com/cannabinoid-biosynthesis-poised-potential-game-changer-drug-development/ \"InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF Profile) has developed a pioneering, high-yield biosynthesis process that enables the manufacture of all 90+ naturally occurring cannabinoids. This groundbreaking development could have an enormous impact in forwarding the efforts of other companies within the cannabis sector.\"Recently, InMed announced the filing of a provisional patent application - the first of many - relating to this proprietary biosynthesis program for manufacturing cannabinoids (http://nnw.fm/Z30dH). Once converted into an international Patent Cooperation Treaty (PCT) application and pursued in key jurisdictions on a global scale, this first patent application will give InMed significant commercial protection for its biosynthesis program, which is an E. coli-based expression system. This series of patent applications will particularly focus on the superiority of E. coli-based expression systems in comparison to other approaches; maximizing production of cannabinoids and related compounds through gene optimization; and additional proprietary developments and data related to InMed's breakthrough biosynthesis program. Over time, InMed intends to actively convert this first patent filing, along with subsequent provisional patents, into national-stage filings in every major commercial jurisdiction.\"About InMed InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel dr...